CSF3 and graft versus host disease: Previous studies comparing total BM vs. total G-CSF MPB sources in the context of HSCT were mainly focused on the overall outcome (i.e. survival, incidence of graft versus host disease and relapse or immune reconstitution)32,55 and commonly based on heterogeneous groups of patients with distinct type of conditioning, disease background/hematological malignancies, prior treatments and transplantation setting (i.e. autologous vs. allogeneic).